AbbVie receives EC approval for Aquipta to treat migraine

AbbVie has received approval from the EC for Aquipta, an oral CGRP receptor antagonist, for the acute treatment of migraine in adults, with or without aura. The decision is supported by results from the Phase III ECLIPSE study, which assessed Aquipta versus placebo for migraine. The ECLIPSE study showed Aquipta was more effective than placebo in achieving pain freedom at two hours after the first migraine attack treatment. Credit: Studio Romantic / Shutterstock.com. AbbVie has received approval from the European Commission (EC) for Aquipta (atogepant), an oral calcitonin gene-related peptide (CGRP) receptor antagonist, for the acute treatment of migraine in…

Source: Pharmaceutical Technology